MX2021000763A - Composicion farmaceutica en la forma de un comprimido masticable de diosmina o de una fraccion flavonoica. - Google Patents
Composicion farmaceutica en la forma de un comprimido masticable de diosmina o de una fraccion flavonoica.Info
- Publication number
- MX2021000763A MX2021000763A MX2021000763A MX2021000763A MX2021000763A MX 2021000763 A MX2021000763 A MX 2021000763A MX 2021000763 A MX2021000763 A MX 2021000763A MX 2021000763 A MX2021000763 A MX 2021000763A MX 2021000763 A MX2021000763 A MX 2021000763A
- Authority
- MX
- Mexico
- Prior art keywords
- pharmaceutical composition
- diosmin
- chewable tablet
- flavonoid moiety
- flavonoid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Physiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Vascular Medicine (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Cardiology (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Una composición farmacéutica en la forma de un comprimido masticable fuertemente dosificado en diosmina micronizada. Esta composición farmacéutica comprende entre un porcentaje de diosmina micronizada entre el 20%y el 80% de la masa total de la composición farmacéutica. Esta composición farmacéutica se utiliza en el tratamiento de la insuficiencia venosa y de la crisis hemorroidal.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1856769A FR3083980B1 (fr) | 2018-07-20 | 2018-07-20 | Composition pharmaceutique sous la forme d'un comprime a croquer de diosmine ou d'une fraction flavonoique |
| PCT/EP2019/069498 WO2020016408A1 (fr) | 2018-07-20 | 2019-07-19 | Composition pharmaceutique sous la forme d'un comprime a croquer de diosmine ou d'une fraction flavonoique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021000763A true MX2021000763A (es) | 2021-03-29 |
Family
ID=65243687
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021000763A MX2021000763A (es) | 2018-07-20 | 2019-07-19 | Composicion farmaceutica en la forma de un comprimido masticable de diosmina o de una fraccion flavonoica. |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP3823588A1 (es) |
| KR (1) | KR20210034036A (es) |
| CN (1) | CN112423735A (es) |
| AR (1) | AR117612A1 (es) |
| AU (1) | AU2019306315B2 (es) |
| BR (1) | BR112021000440A2 (es) |
| CA (1) | CA3106495C (es) |
| CL (1) | CL2021000083A1 (es) |
| CO (1) | CO2021000115A2 (es) |
| CR (1) | CR20210023A (es) |
| EA (1) | EA202190269A1 (es) |
| EC (1) | ECSP21001232A (es) |
| FR (1) | FR3083980B1 (es) |
| JO (1) | JOP20210003A1 (es) |
| MA (1) | MA53159A (es) |
| MX (1) | MX2021000763A (es) |
| NI (1) | NI202100002A (es) |
| PE (1) | PE20210929A1 (es) |
| PH (1) | PH12021550037A1 (es) |
| SG (1) | SG11202100181YA (es) |
| TW (1) | TWI831808B (es) |
| WO (1) | WO2020016408A1 (es) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2661610B1 (fr) * | 1990-05-02 | 1994-09-30 | Rhone Poulenc Sante | Nouvelle forme lyophilisee de la diosmine et sa preparation. |
| FR2661830B1 (fr) * | 1990-05-11 | 1992-09-04 | Corbiere Jerome | Nouvelle compositions pharmaceutiques a base de flavonoside. |
| FR2726469B1 (fr) | 1994-11-08 | 1996-12-13 | Adir | Composition pharmaceutique pour l'administration orale de flavonoides |
| FR2845597B1 (fr) | 2002-10-11 | 2005-03-11 | Innothera Lab Sa | Formulation orale seche contenant de la diosmine sous forme pharmaceutique de comprime a croquer |
| ITMI20050517A1 (it) | 2005-03-30 | 2006-09-30 | Therapicon Srl | Composizione farmaceutica di una tipica frazione microcristallina di flavonoidi |
| FR2999934B1 (fr) * | 2012-12-21 | 2015-02-20 | Servier Lab | Composition pharmaceutique sous la forme d'une suspension orale comprenant une fraction flavonoique et de la gomme xanthane |
-
2018
- 2018-07-20 FR FR1856769A patent/FR3083980B1/fr active Active
-
2019
- 2019-07-19 TW TW108125532A patent/TWI831808B/zh active
- 2019-07-19 JO JOP/2021/0003A patent/JOP20210003A1/ar unknown
- 2019-07-19 PE PE2021000077A patent/PE20210929A1/es unknown
- 2019-07-19 CN CN201980047436.7A patent/CN112423735A/zh active Pending
- 2019-07-19 AR ARP190102031A patent/AR117612A1/es unknown
- 2019-07-19 WO PCT/EP2019/069498 patent/WO2020016408A1/fr unknown
- 2019-07-19 CA CA3106495A patent/CA3106495C/fr active Active
- 2019-07-19 MA MA053159A patent/MA53159A/fr unknown
- 2019-07-19 EP EP19742363.5A patent/EP3823588A1/fr active Pending
- 2019-07-19 BR BR112021000440-8A patent/BR112021000440A2/pt unknown
- 2019-07-19 AU AU2019306315A patent/AU2019306315B2/en active Active
- 2019-07-19 KR KR1020217004706A patent/KR20210034036A/ko active Search and Examination
- 2019-07-19 CR CR20210023A patent/CR20210023A/es unknown
- 2019-07-19 EA EA202190269A patent/EA202190269A1/ru unknown
- 2019-07-19 SG SG11202100181YA patent/SG11202100181YA/en unknown
- 2019-07-19 MX MX2021000763A patent/MX2021000763A/es unknown
-
2021
- 2021-01-07 PH PH12021550037A patent/PH12021550037A1/en unknown
- 2021-01-08 NI NI202100002A patent/NI202100002A/es unknown
- 2021-01-08 CO CONC2021/0000115A patent/CO2021000115A2/es unknown
- 2021-01-08 EC ECSENADI20211232A patent/ECSP21001232A/es unknown
- 2021-01-12 CL CL2021000083A patent/CL2021000083A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019306315B2 (en) | 2023-03-09 |
| AU2019306315A1 (en) | 2021-02-11 |
| BR112021000440A2 (pt) | 2021-04-06 |
| TWI831808B (zh) | 2024-02-11 |
| AR117612A1 (es) | 2021-08-18 |
| EP3823588A1 (fr) | 2021-05-26 |
| FR3083980A1 (fr) | 2020-01-24 |
| PH12021550037A1 (en) | 2021-09-27 |
| FR3083980B1 (fr) | 2021-04-16 |
| PE20210929A1 (es) | 2021-05-19 |
| NI202100002A (es) | 2021-06-22 |
| TW202019439A (zh) | 2020-06-01 |
| CL2021000083A1 (es) | 2021-07-30 |
| EA202190269A1 (ru) | 2021-06-15 |
| JOP20210003A1 (ar) | 2021-01-10 |
| WO2020016408A1 (fr) | 2020-01-23 |
| MA53159A (fr) | 2021-05-26 |
| CR20210023A (es) | 2021-02-22 |
| CA3106495A1 (fr) | 2020-01-23 |
| KR20210034036A (ko) | 2021-03-29 |
| CN112423735A (zh) | 2021-02-26 |
| SG11202100181YA (en) | 2021-02-25 |
| CA3106495C (fr) | 2023-08-08 |
| ECSP21001232A (es) | 2021-02-26 |
| CO2021000115A2 (es) | 2021-01-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202110659B (en) | Methods of reducing the risk of cardiovascular events in a subject | |
| EP4223316A3 (en) | Improved antibody-oligonucleotide conjugate | |
| CL2019000209A1 (es) | Formulación novedosa administrable por la vía oral. | |
| EA201690102A1 (ru) | Фармацевтическая композиция, содержащая диметилфумарат, для введения в низкой суточной дозе | |
| MX2020008258A (es) | Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos. | |
| WO2018165404A8 (en) | Pharmaceutical formulations of phloroglucinol and trimethylphloroglucinol | |
| PH12019501371A1 (en) | PYRIMIDINE TRICYCLIC ENONE DERIVATIVES FOR INHIBITION OF RORy AND OTHERS USES | |
| PH12020500543A1 (en) | Nonracemic mixtures and uses thereof | |
| HRP20192189T1 (hr) | Doziranja i terapijske primjene l-4-klorokinurenina | |
| ES2062100T3 (es) | Empleo de acetil l-carnitina en el tratamiento terapeutico de cataratas y composiciones farmaceuticas utiles en este tratamiento. | |
| MX2021014774A (es) | Formulaciones de liberacion modificada y usos de las mismas. | |
| BR112021017957A2 (pt) | Derivado tienoeterocíclico, método de preparação do mesmo e uso médico do mesmo | |
| ZA201905212B (en) | Rescue treatment of post operative nausea and vomiting | |
| MX2021000763A (es) | Composicion farmaceutica en la forma de un comprimido masticable de diosmina o de una fraccion flavonoica. | |
| MX2024001832A (es) | Nueva composicion farmaceutica oral para terapias contra el cancer. | |
| MX2015010594A (es) | Esteres de testosterona de cadena larga lipobalanceados para suministro oral. | |
| CL2022000095A1 (es) | Composiciones farmacéuticas resistentes a la descarga de dosis que comprenden venirunad | |
| BR112015028302A2 (pt) | formulação de pastilha de nicotina | |
| MX2023001232A (es) | Medicamentos antiplaquetarios y usos de estos. | |
| DOP2021000069A (es) | Derivados de 4 pirazin-2-ilmetil-morfolina y su uso como medicamento | |
| MX2021006464A (es) | Forma polimorfica de meisoindigo y formulacion modificada de meisoindigo. | |
| TN2016000179A1 (en) | Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor. | |
| GB976096A (en) | Pharmaceutical compositions | |
| WO2022123550A8 (en) | Cannabidiol for augmenting vaccine mediated immunity and prophylaxis of covid-19 | |
| PH12019501607A1 (en) | Tapentadol nasal composition |